{"id":"W4376107652","doi":"10.1056/nejmoa2212851","title":"Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma","year":2023,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":158,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"Istituto Oncologico Veneto; Institut Gustave-Roussy; Université Paris-Saclay; National Cancer Institute; Cancer Research UK; Dana-Farber/Harvard Cancer Center; Bristol-Myers Squibb; Queen Mary University of London; Exelixis; Memorial Sloan-Kettering Cancer Center; Brigham and Women's Hospital","keywords":"Cabozantinib; Nivolumab; Ipilimumab; Renal cell carcinoma; Medicine; Oncology; Axitinib; Internal medicine; Immunotherapy; Sunitinib; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009795463,0.000226117,0.0007996262,0.0007060808,0.0000393017,0.000009112505,0.000104569,0.00009165334,0.0001165571],"category_scores_gemma":[0.0002244932,0.0001488149,0.00008578524,0.0005515649,0.0001148413,0.00008189511,0.00004300301,0.0004790127,0.00002014422],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001506469,"about_ca_system_score_gemma":0.0003686359,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00040927,"about_ca_topic_score_gemma":0.00008073697,"domain_scores_codex":[0.9979731,0.00009884322,0.0007297159,0.0002204931,0.0006286133,0.000349267],"domain_scores_gemma":[0.9985847,0.0002708143,0.0002712157,0.0002335251,0.0001421984,0.0004974881],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01571585,0.0005819753,0.379491,0.0010133,0.0003869533,0.06421685,0.01902014,0.0002924563,0.1414684,0.0001913479,0.1094482,0.2681735],"study_design_scores_gemma":[0.3898842,0.01067449,0.5257383,0.001468949,0.0007112413,0.0129905,0.001658566,0.0006434262,0.01403457,0.0005154793,0.04131183,0.0003683965],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9828386,0.004839643,0.0000219446,0.006708737,0.000375418,0.0002258119,0.000001540604,0.00002197476,0.004966351],"genre_scores_gemma":[0.9931451,0.0009999538,0.0002872541,0.0002443762,0.001603717,0.000002013743,0.00001073207,0.00003109605,0.003675728],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3741684,"threshold_uncertainty_score":0.6068497,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02772866227719734,"score_gpt":0.2713468021366063,"score_spread":0.2436181398594089,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}